Unknown NA INTERVENTIONAL 1-arm NCT01801852

Autologous Natural Killer T Cells Infusion for the Treatment of Cancer

Phase 1 Study of Autologous Natural Killer T Cells Infusion in Treating Patients With Tumors

Sponsor: Chinese PLA General Hospital

Conditions Breast Cancer Colon Cancer Glioma Hepatocellular Cancer Pancreatic Cancer Prostate Cancer Squamous Cell Lung Cancer

Interventions NKT cells

Updated 6 times since 2017 Last updated: Jan 26, 2016 Started: Jan 31, 2013 Primary completion: May 31, 2016 Completion: Jun 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Breast Cancer and Colon Cancer, this trial is ongoing. The trial is conducted by Chinese PLA General Hospital and has accumulated 6 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status NA
Jun 2018 — Jan 2021 [monthly]

Unknown Status NA
Feb 2018 — Jun 2018 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status

▶ Show 1 earlier version

Jan 2017 — Feb 2018 [monthly]

Recruiting NA

First recorded

Jan 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese PLA General Hospital
Tsinghua University

Data source: Chinese PLA General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China